Permeação cutânea e vaginal de fármacos: rotas alternativas
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora (UFJF)
DOI
Abstract
In Chapter 1, the objective was to insert taxifoline (TAX) into a semi-solid dosage
form and to evaluate its ex vivo permeation in human skin. TAX was incorporated
into an oil-in-water emulsion. Analysis Method was developed and validated using
high performance liquid chromatography (HPLC) to active principle quantification
during the experiments and permeation through the human skin was conducted in
Franz-type cells. In the chromatographic method the following conditions were used:
octadecylsilane (C18) column; mobile phase consisting of water and acetonitrile
(45:55, v/v), acidified with 0.1 % formic acid (pH = 2,4); column compartment
temperature to 45 ° C; an isocratic flow system at 0,5 mL.min-1 and detection at 288
nm. The method was precise (CV<5 %), accurate (recovery between 98 % and 102
%), linear (R2>0,99), specific, and robust. Permeation experiment through human
skin presented permeated percentage equal to 48,09 % (per dose). The results
described suggest that, in the studied matrix, TAX may be able to permeate up to the
dermis and that, possibly, TAX achieved concentrations may be sufficient for the
same to exert its therapeutic effect systemically. In Chapter 2, the objective of the
study was to evaluate the feasibility of using formulations containing dienogest
(DNG), gestrinone (GTN), nimesulide (NMS) and piroxicam (PRX) for vaginal
administration in patients with pelvic pain associated with endometriosis. Intravaginal
creams were individually composed of active pharmaceutical ingredients
incorporated into Pentravan® base (0,2 % DNG, 0,5 % GTN, 2,0 % NMS and 2,0 %
PRX). Methods of quantification using HPLC were validated for the quantification of
active principles, vaginal permeation profiles were determined using porcine vaginal
mucosa in Franz type diffusion cells and kinetic parameters were determined.
Methods were precise (CV <5 %), exact (recovery between 98 % and 102 %), linear
(R2> 0,99) and specific. Diffusion experiments demonstrated fluxes of 15,98 μg.cm-
2.h-1 for DNG, 3,91 μg.cm-2.h-1 for PRX, 3,72 μg.cm-2.h-1 for GTN and 2,26 μg.cm-2.h-1
for NMS. Fluxes required to release the recommended daily dose for the treatment of
pelvic pain associated with endometriosis were calculated and established as 0,87
μg.cm-2.h-1 for DNG, 0,69 μg.cm-2.h-1 for GTN, 70,45 μg.cm-2.h-1 for NMS and 9,64
μg.cm-2.h-1 for PRX. DNG and GTN had permeation fluxes and quantities of drug
absorbed hypothetically compatible with therapeutic effect in vivo, whereas NMS and
PRX studies showed a great amount of these drugs retained in the vaginal mucosa
which could explain a local effect for these two substances. The results suggest that
the matrix evaluated appears to be a viable intravaginal vehicle for the systemic
therapeutic use of DNG and GTN. However, NMS and PRX demonstrated the
possibility of use for an effect on the local tissue. Further studies should be
performed in the formulation for systemic therapeutic use of NMS and PRX.
Description
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Rights and licensing
Acesso Aberto
